The anesthetic ketamine is being hailed as a breakthrough therapy for people with post-traumatic stress disorder (PTSD), treatment-resistant depression and other mood disorders.

BD affects millions but remains misunderstood, underdiagnosed, and underfunded. Researchers are working to change this by ...

Axsome settles Auvelity patent litigation with Teva, delaying a generic launch until 2038. Analysts see growth potential with Symbravo's migraine approval.

Biohaven's NDA for Troriluzole was accepted by the FDA, potentially leading to approval in Q3 2025. Click here to find out ...

Neumora Therapeutics Inc. concealed critical issues with its flagship clinical depression drug’s Phase 2 trial, contributing ...

Neurocrine Biosciences Q4 earnings topped forecasts, but revenue slightly missed. Analysts see Ingrezza's long-term growth ...

Federal authorities say two shipments containing a deadly, addictive and illegal substance was seized at the port of Cincinnati.

Naloxone is a fantastic tool in reducing opioid deaths, but gentler versions would be helpful for fighting overdose ...

One of DOGE's engineers dispatched to take over the Education Department used to have a very different title: ketamine dealer ...

The American Society of Anesthesiologists has issued new guidance on ketamine administration for patients suffering from post-traumatic stress disorder, treatment-resistant depression and other mood ...

U.S. Customs and Border Protection (CBP) officers in Cincinnati intercepted two shipments of deadly tianeptine, known on the ...

Also Read: Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights Ingrezza fourth-quarter net product sales grew 23% compared to fourth quarter 2023, driven by ...